AAAAAA
Results:
1-15
|
Results: 15
Authors:
Wilder, RB
Jones, D
Tucker, SL
Fuller, LM
Ha, CS
McLaughlin, P
Hess, MA
Cabanillas, F
Cox, JD
Citation: Rb. Wilder et al., Long-term results with radiotherapy for stage I-II follicular lymphomas, INT J RAD O, 51(5), 2001, pp. 1219-1227
Authors:
Wilder, RB
Rodriguez, MA
Tucker, SL
Ha, CS
Hess, MA
Cabanillas, FF
Cox, JD
Citation: Rb. Wilder et al., Radiation therapy after a partial response to chop chemotherapy for aggressive lymphomas, INT J RAD O, 50(3), 2001, pp. 743-749
Authors:
Wilder, RB
Tucker, SL
Ha, CS
Rodriguez, MA
Hess, MA
Cabanillas, FF
Cox, JD
Citation: Rb. Wilder et al., Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to chop-based induction chemotherapy, INT J RAD O, 49(1), 2001, pp. 17-22
Authors:
Pelloski, CE
Wilder, RB
Ha, CS
Hess, MA
Cabanillas, FF
Cox, JD
Citation: Ce. Pelloski et al., Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment, RADIOTH ONC, 59(2), 2001, pp. 145-151
Authors:
Ha, CS
Tucker, SL
Blanco, AI
Wilder, RB
McLaughlin, P
Cabanillas, F
Cox, JD
Citation: Cs. Ha et al., Hematologic recovery after central lymphatic irradiation for patients withstage I-II follicular lymphoma, CANCER, 92(5), 2001, pp. 1074-1079
Authors:
Chronowski, M
Ha, CS
Wilder, RB
Cabanillas, F
Manning, J
Cox, JD
Citation: M. Chronowski et al., Treatment of unicentric and multicentric Castleman disease and the role ofradiotherapy, CANCER, 92(3), 2001, pp. 670-676
Authors:
Ha, CS
Shadle, KM
Medeiros, LJ
Wilder, RB
Hess, MA
Cabanillas, F
Cox, JD
Citation: Cs. Ha et al., Localized non-Hodgkin lymphoma involving the thyroid gland, CANCER, 91(4), 2001, pp. 629-635
Authors:
Wilder, RB
Rodriguez, MA
Ha, CS
Pro, B
Hess, MA
Cabanillas, F
Cox, JD
Citation: Rb. Wilder et al., Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma, CANCER, 91(12), 2001, pp. 2440-2446
Authors:
Schlembach, PJ
Wilder, RB
Tucker, SL
Ha, CS
Rodriguez, MA
Hess, MA
Cabanillas, FF
Cox, JD
Citation: Pj. Schlembach et al., Impact of involved field radiotherapy after chop-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas, INT J RAD O, 48(4), 2000, pp. 1107-1110
Authors:
Chou, RH
Wilder, RB
Ji, M
Ryu, JK
Leigh, BR
Earle, JD
Doggett, RLS
Kubo, HD
Roach, M
White, RWD
Citation: Rh. Chou et al., Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy, INT J RAD O, 47(1), 2000, pp. 115-119
Authors:
Michalski, JM
Purdy, JA
Winter, K
Roach, M
Vijayakumar, S
Sandler, HM
Markoe, AM
Ritter, MA
Russell, KJ
Sailer, S
Harms, WB
Perez, CA
Wilder, RB
Hanks, GE
Cox, JD
Citation: Jm. Michalski et al., Preliminary report of toxicity following 3D radiation therapy for prostatecancer on 3DOG/RTOG 9406, INT J RAD O, 46(2), 2000, pp. 391-402
Authors:
Wilder, RB
Chou, RH
Ryu, JK
Stern, RL
Wong, MS
Ji, M
Roach, M
White, RD
Citation: Rb. Wilder et al., Potency preservation after three-dimensional conformal radiotherapy for prostate cancer - Preliminary results, AM J CL ONC, 23(4), 2000, pp. 330-333
Authors:
Wilder, RB
Hsiang, JY
Ji, M
Earle, JD
White, RD
Citation: Rb. Wilder et al., Preliminary results of three-dimensional conformal radiotherapy as salvagetreatment for a rising prostate-specific antigen level postprostatectomy, AM J CL ONC, 23(2), 2000, pp. 176-180
Authors:
Wilder, RB
Shen, S
DeNardo, G
Citation: Rb. Wilder et al., Dosimetry for radioimmunotherapy: A rapidly evolving field, CANC BIO R, 14(2), 1999, pp. 67-70
Authors:
Kubo, HD
Wilder, RB
Pappas, CTE
Citation: Hd. Kubo et al., Impact of collimator leaf width on stereotactic radiosurgery and 3D conformal radiotherapy treatment plans, INT J RAD O, 44(4), 1999, pp. 937-945
Risultati:
1-15
|